The Daily Delegate

February 16, 2026

By Sarem Assefa

In today’s economic and financial climate, the majority of Californians, (& Americans in general) are burdened by increasing commercial stains regarding medications distributed by pharmacies nationwide. With a significant increase in pricing starting from the late ‘80s, medicated drugs like EpiPens have spiked by over 500% from 2007 to 2016. Our bill proposes  the implementation of annulment regarding pharmaceutical manufacturing companies profiting more than 200% with sales in contrast to original cost. Following its imposition in 2027, said bill would attend to access for vital medication, & prioriize the general population of Californians facing increasing healthcare costs. 

In an article written by Dan Witters for Gallup, the statistic of Americans unable to afford healthcare was about 18%, equating to that of 46 million people.  Mylan, a major pharmaceutical manufacturing company, faced heavy criticism from the media following a significant uptick in EpiPen pricing. In response, a generic variant of their bestseller was mass-produced for half the price. If imposed, our bill would serve as a repeal to the financial & economic injustices of the health care network, & the ratification of obligatory morality.